32 results
424B5
a20mt1qvub247d vjmal
24 Mar 22
Prospectus supplement for primary offering
4:15pm
PRE 14A
9zyo59v0ndcw jl54
1 Sep 21
Preliminary proxy
4:46pm
424B5
539sp1xvogyq got3kg
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-10.1
ym930ld
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-99.1
dnuxv1f4f75kr3 y2y
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
424B3
hdxi utn34ou5
12 Apr 21
Prospectus supplement
1:44pm
S-3
b2ibyx
2 Apr 21
Shelf registration
12:00am